These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21831545)

  • 21. Novel and bone-targeted agents for CRPC.
    Fizazi K; Albiges L; Massard C; Escudier B; Loriot Y
    Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Promising on advanced cancer, several new drugs coming].
    Widmark A; Karlsson CT
    Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment sequencing in metastatic castrate-resistant prostate cancer.
    Sartor O; Gillessen S
    Asian J Androl; 2014; 16(3):426-31. PubMed ID: 24675654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contemporary management of metastatic castration-resistant prostate cancer.
    Sonpavde G; Sternberg CN
    Curr Opin Urol; 2011 May; 21(3):241-7. PubMed ID: 21455038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New agents for the management of castration-resistant prostate cancer.
    Cersosimo RJ
    Ann Pharmacother; 2012 Nov; 46(11):1518-28. PubMed ID: 23136351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
    Wilson L; Tang J; Zhong L; Balani G; Gipson G; Xiang P; Yu D; Srinivas S
    J Oncol Pharm Pract; 2014 Dec; 20(6):417-25. PubMed ID: 24243919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New treatments for castration-resistant prostate cancer].
    Sautois B; Gennigens C
    Rev Med Liege; 2013 Feb; 68(2):94-6. PubMed ID: 23469490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.
    Yin L; Hu Q; Hartmann RW
    Int J Mol Sci; 2013 Jul; 14(7):13958-78. PubMed ID: 23880851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
    Sartor O; Michels RM; Massard C; de Bono JS
    Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel molecular targets for the therapy of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sternberg CN
    Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer.
    Peters ML; de Meijer C; Wyndaele D; Noordzij W; Leliveld-Kors AM; van den Bosch J; van den Berg PH; Baka A; Gaultney JG
    Appl Health Econ Health Policy; 2018 Feb; 16(1):133-143. PubMed ID: 28866822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abiraterone and its place in the treatment of metastatic CRPC.
    Sartor O; Pal SK
    Nat Rev Clin Oncol; 2013 Jan; 10(1):6-8. PubMed ID: 23149889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use.
    Gravanis I; Lopez AS; Hemmings RJ; Jiménez JC; Garcia-Carbonero R; Gallego IG; Giménez EV; O'Connor D; Giuliani R; Salmonson T; Pignatti F
    Oncologist; 2013; 18(9):1032-42. PubMed ID: 23966222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Second line therapy for castration-resistant prostate cancer (CRPC)].
    Molitor B; Börgermann C
    Urologe A; 2012 Mar; 51(3):357-62. PubMed ID: 22113549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.
    Zhong L; Pon V; Srinivas S; Nguyen N; Frear M; Kwon S; Gong C; Malmstrom R; Wilson L
    PLoS One; 2013; 8(5):e64275. PubMed ID: 23717582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
    Mezynski J; Pezaro C; Bianchini D; Zivi A; Sandhu S; Thompson E; Hunt J; Sheridan E; Baikady B; Sarvadikar A; Maier G; Reid AHM; Mulick Cassidy A; Olmos D; Attard G; de Bono J
    Ann Oncol; 2012 Nov; 23(11):2943-2947. PubMed ID: 22771826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
    Dyer M; Rinaldi F; George E; Adler AI
    Lancet Oncol; 2012 Aug; 13(8):762-3. PubMed ID: 23024987
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.
    Gong CL; Hay JW
    J Natl Compr Canc Netw; 2014 Oct; 12(10):1417-25. PubMed ID: 25313181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.